ClinicalTrials.gg
Active, not recruitingNCT07104500VANQUISH 1Updated Nov 24, 2025

VK2735 for Weight Management Phase 3

A Phase 3 interventional study of VK2735 in Weight Loss, sponsored by Viking Therapeutics, Inc.. Active, not recruiting at 137 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by Viking Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4,500
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 998 studies in Weight Loss with a site in United States — 117 open to participants now, 172 under way, 8 of them phase 3. Weight Loss · United States.

Planned enrollment
7th of 915
4,500 · median 72
Started
2025
with 54 others
Phase 3
32 of 998
3 open now
Primary completion
2027-07
later than 82 of 171 live
Registered
933rd of 998
by date

Among the 998 studies in Weight Loss with a site in United States, this one is the 7th largest by planned enrollment of the 915 interventional ones that give a count, is one of 55 that started in 2025, is one of 32 in phase 3, reaches primary completion later than 82 of the 171 other live ones, and was the 933rd registered.

Weight Loss

1,818 studies on the registry are indexed under Weight Loss; 296 are open to participants now.

Browse Weight Loss studies →

Open to participants now

117 of the 998 studies in Weight Loss with a site in United States are open now. Recruiting first, the newest first:

112 more — sign in →

All 117 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 199 Weight Loss studies recruiting now, 73 (37%) set no upper age limit and 109 (55%) stop at 75 or younger; 21 take children under 18; 57 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 998 studies in Weight Loss with a site in United States, or all of them as a file.
02

Study summary

This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes.

03

Conditions studied

  • Weight Loss

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years of age at the time of signing the
  2. (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co- morbid condition (treated or untreated)

    • Weight-related co-morbid conditions include hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease
    • Cardiovascular disease includes, for example, ischemic cardiovascular disease, (NYHA) Functional Class I-III heart failure
    • BMI calculated at the Screening visit will be used to determine eligibility

Exclusion criteria

Exclusion Criteria:

  1. History of or current medical disorder that, in the opinion of the Investigator, does not support study participation
  2. Self-reported body weight change of 5% or more within 3 months of screening
  3. Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty if performed >1 year prior to screening)
  4. Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as, mucosa ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)
  5. Current or past diagnosis of diabetes mellitus (including type 1, type 2, except gestational diabetes)
  6. Treatment with glucose-lowering agent(s) within 90 days before screening
  7. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
  8. History of acute or chronic pancreatitis
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
4,500 participants (estimated)

Study arms

  • Placebo comparator
    Placebo Assignment

    VK2735 Placebo Comparator Once Weekly

    Drug: VK2735

  • Experimental
    Active Assignment (Dose 1)

    VK2735 7.5mg Once Weekly

    Drug: VK2735

  • Experimental
    Active Assignment (Dose 2)

    VK2735 12.5mg Once Weekly

    Drug: VK2735

  • Experimental
    Active Assignment (Dose 3)

    VK2735 17.5mg Once Weekly

    Drug: VK2735

Interventions

  • DrugVK2735

    VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly

06

What researchers measure

Primary outcomes

  1. Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment

    Time frame: 78 Weeks

Secondary outcomes

  1. Percentage of participants who achieve ≥5%, ≥10%, ≥15% and ≥20% body weight reduction after 78 weeks of treatment

    Time frame: 78 Weeks

07

Study locations

137 sites
  • Viking Clinical Site #1037
    Birmingham, Alabama 35235, United States
  • Viking Clinical Site #1064
    Birmingham, Alabama 35249, United States
  • Viking Clinical Site #1128
    Huntsville, Alabama 35801, United States
  • Viking Clinical Site #1081
    Mobile, Alabama 36608, United States
  • Viking Clinical Site #1005
    Chandler, Arizona 85210, United States
  • Viking Clinical Site #1017
    Flagstaff, Arizona 86001, United States
  • Viking Clinical Site #1018
    Peoria, Arizona 85381, United States
  • Viking Clinical Site #1135
    Scottsdale, Arizona 85260, United States
  • Viking Clinical Site #1019
    Tucson, Arizona 85711, United States
  • Viking Clinical Site #1036
    Little Rock, Arkansas 72211, United States
  • Viking Clinical Site #1071
    Chula Vista, California 91911, United States
  • Viking Clinical Site #1070
    Escondido, California 92025, United States
  • Viking Clinical Site #1054
    Huntington Park, California 90255, United States
  • Viking Clinical Site #1014
    Lake Forest, California 92630, United States
  • Viking Clinical Site #1129
    Lemon Grove, California 91945, United States
  • Viking Clinical Site #1051
    Lincoln, California 95648, United States
  • Viking Clinical Site #1050
    Long Beach, California 90815, United States
  • Viking Clinical Site #1055
    Los Angeles, California 90057, United States
  • Viking Clinical Site #1078
    Manteca, California 95336, United States
  • Viking Clinical Site #1053
    Montclair, California 91763, United States
  • Viking Clinical Site #1068
    Panorama City, California 91402, United States
  • Viking Clinical Site #1132
    Rolling Hills Estates, California 90274, United States
  • Viking Clinical Site #1131
    San Diego, California 92103, United States
  • Viking Clinical Site #1104
    Santa Maria, California 93458, United States
  • Viking Clinical Site #1052
    Spring Valley, California 91978, United States
  • Viking Clinical Site #1109
    Tustin, California 92780, United States
  • Viking Clinical Site #1067
    Van Nuys, California 91405, United States
  • Viking Clinical Site #1079
    Walnut Creek, California 94598, United States
  • Viking Clinical Site #1119
    Denver, Colorado 80210, United States
  • Viking Clinical Site #1123
    Washington D.C., District of Columbia 20036, United States
  • Viking Clinical Site #1013
    Clearwater, Florida 33756, United States
  • Viking Clinical Site #1121
    Clearwater, Florida 33761, United States
  • Viking Clinical Site #1003
    Cooper City, Florida 33024, United States
  • Viking Clinical Site #1112
    DeLand, Florida 32720, United States
  • Viking Clinical Site #1107
    Delray Beach, Florida 33445, United States
  • Viking Clinical Site #1083
    Fort Myers, Florida 33912, United States
  • Viking Clinical Site #1058
    Jacksonville, Florida 32216, United States
  • Viking Clinical Site #1076
    Lakeland, Florida 33803, United States
  • Viking Clinical Site #1060
    Lakewood Rch, Florida 34211, United States
  • Viking Clinical Site #1117
    Miami, Florida 33122, United States
  • Viking Clinical Site #1059
    New Port Richey, Florida 34652, United States
  • Viking Clinical Site #1012
    Ocoee, Florida 34761, United States
  • Viking Clinical Site #1056
    Palmetto Bay, Florida 33157, United States
  • Viking Clinical Site #1011
    Port Orange, Florida 32127, United States
  • Viking Clinical Site #1057
    West Palm Beach, Florida 33407, United States
  • Viking Clinical Site #1116
    Atlanta, Georgia 30329, United States
  • Viking Clinical Site #1030
    Columbus, Georgia 31904, United States
  • Viking Clinical Site #1120
    Rincon, Georgia 31326, United States
  • Viking Clinical Site #1093
    Savannah, Georgia 31406, United States
  • Viking Clinical Site #1025
    Woodstock, Georgia 30189, United States
  • Viking Clinical Site #1062
    Honolulu, Hawaii 96814, United States
  • Viking Clinical Site #1080
    Meridian, Idaho 83642, United States
  • Viking Clinical Site #1006
    Chicago, Illinois 60607, United States
  • Viking Clinical Site #1090
    Chicago, Illinois 60640, United States
  • Viking Clinical Site #1138
    Westmont, Illinois 60559, United States
  • Viking Clinical Site #1127
    Valparaiso, Indiana 46383, United States
  • Viking Clinical Site #1022
    West Des Moines, Iowa 50266, United States
  • Viking Clinical Site #1099
    Wichita, Kansas 67207, United States
  • Viking Clinical Site #1069
    Lexington, Kentucky 40509, United States
  • Viking Clinical Site #1040
    Lexington, Kentucky 40513, United States
  • Viking Clinical Site #1009
    Louisville, Kentucky 40213, United States
  • Viking Clinical Site #1118
    Baton Rouge, Louisiana 70808, United States
  • Viking Clinical Site #1139
    Baton Rouge, Louisiana 70809, United States
  • Viking Clinical Site #1106
    Lafayette, Louisiana 70508, United States
  • Viking Clinical Site #1020
    Metairie, Louisiana 70006, United States
  • Viking Clinical Site #1087
    Monroe, Louisiana 71201, United States
  • Viking Clinical Site #1094
    Chevy Chase, Maryland 20815, United States
  • Viking Clinical Site #1066
    Rockville, Maryland 20854, United States
  • Viking Clinical Site #1103
    Boston, Massachusetts 02114, United States
  • Viking Clinical Site #1001
    Methuen, Massachusetts 01844, United States
  • Viking Clinical Site #1136
    Needham, Massachusetts 02492, United States
  • Viking Clinical Site #1038
    Ypsilanti, Michigan 48197, United States
  • Viking Clinical Site #1140
    Gulfport, Mississippi 39503, United States
  • Viking Clinical Site #1031
    City of Saint Peters, Missouri 63303, United States
  • Viking Clinical Site #1016
    Kansas City, Missouri 64131, United States
  • Viking Clinical Site #1125
    Springfield, Missouri 65807, United States
  • Viking Clinical Site #1108
    St Louis, Missouri 63108, United States
  • Viking Clinical Site #1010
    Butte, Montana 59701, United States
  • Viking Clinical Site #1075
    Omaha, Nebraska 68134, United States
  • Viking Clinical Site #1035
    Las Vegas, Nevada 89148, United States
  • Viking Clinical Site #1034
    Reno, Nevada 89511, United States
  • Viking Clinical Site #1065
    Lebanon, New Hampshire 03756, United States
  • Viking Clinical Site #1095
    Marlton, New Jersey 08009, United States
  • Viking Clinical Site #1029
    Albuquerque, New Mexico 87109, United States
  • Viking Clinical Site #1088
    Albany, New York 12205, United States
  • Viking Clinical Site #1042
    East Syracuse, New York 13057, United States
  • Viking Clinical Site #1096
    Hartsdale, New York 10530, United States
  • Viking Clinical Site #1133
    New York, New York 10036, United States
  • Viking Clinical Site #1142
    New York, New York 10065, United States
  • Viking Clinical Site #1021
    The Bronx, New York 10455, United States
  • Viking Clinical Site #1032
    Westfield, New York 14787, United States
  • Viking Clinical Site #1141
    Charlotte, North Carolina 28250, United States
  • Viking Clinical Site #1122
    Durham, North Carolina 27701, United States
  • Viking Clinical Site #1144
    Fayetteville, North Carolina 28304, United States
  • Viking Clinical Site #1026
    Greensboro, North Carolina 27410, United States
  • Viking Clinical Site #1110
    Morehead City, North Carolina 28557, United States
  • Viking Clinical Site #1061
    Morehead City, North Carolina 28857, United States
  • Viking Clinical Site #1027
    Fargo, North Dakota 58104, United States
  • Viking Clinical Site #1043
    Cincinnati, Ohio 45219, United States
  • Viking Clinical Site #1074
    Cincinnati, Ohio 45242, United States

Showing the first 100 of 137 sites across 2 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jul 2027, 24 months after the start.

Of 23 phase 3 interventional studies under Weight Loss, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's planned 24 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2025
First posted
Aug 5, 2025
StartActual
Jun 23, 2025
Primary completionEst.
Jul 1, 2027
CompletionEst.
Aug 1, 2027
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07104500
Responsible party
Sponsor
First posted
Aug 5, 2025
Start date
Jun 23, 2025
Primary completion
Jul 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Nov 24, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VK2735

Start the discussion